| Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] |
| | | | | | | | | | | | | | | | | | | | 2014 | | 2013 | | 2012 | Segment revenue—to unaffiliated customers: | | | | | | | Human pharmaceutical products: | | | | | | | | | | | | | | Endocrinology: | | | | | | | Humalog® | | $ | 2,785.2 |
| | $ | 2,611.2 |
| | $ | 2,395.5 |
| Humulin® | | 1,400.1 |
| | 1,315.8 |
| | 1,239.1 |
| Forteo® | | 1,322.0 |
| | 1,244.9 |
| | 1,151.0 |
| Evista | | 419.8 |
| | 1,050.4 |
| | 1,010.1 |
| Trajenta | | 328.8 |
| | 249.2 |
| | 88.6 |
| Other Endocrinology | | 683.1 |
| | 832.9 |
| | 926.6 |
| Total Endocrinology | | 6,939.0 |
| | 7,304.4 |
| | 6,810.9 |
| | | | | | | | Neuroscience: | | | | | | | Cymbalta | | 1,614.7 |
| | 5,084.4 |
| | 4,994.1 |
| Zyprexa® | | 1,037.3 |
| | 1,194.8 |
| | 1,701.4 |
| Strattera® | | 738.5 |
| | 709.2 |
| | 621.4 |
| Other Neuroscience | | 206.0 |
| | 227.8 |
| | 258.2 |
| Total Neuroscience | | 3,596.5 |
| | 7,216.2 |
| | 7,575.1 |
| | | | | | | |
| | | | | | | | | | | | | | | | | | | | 2014 | | 2013 | | 2012 | Oncology: | | | | | | | Alimta | | 2,792.0 |
| | 2,703.0 |
| | 2,594.3 |
| Erbitux | | 373.3 |
| | 373.7 |
| | 397.0 |
| Other Oncology | | 227.7 |
| | 191.8 |
| | 290.3 |
| Total Oncology | | 3,393.0 |
| | 3,268.5 |
| | 3,281.6 |
| | | | | | | | Cardiovascular: | | | | | | | Cialis® | | 2,291.0 |
| | 2,159.4 |
| | 1,926.8 |
| Effient | | 522.2 |
| | 508.7 |
| | 457.2 |
| Other Cardiovascular | | 240.3 |
| | 255.1 |
| | 248.5 |
| Total Cardiovascular | | 3,053.5 |
| | 2,923.2 |
| | 2,632.5 |
| | | | | | | | Other pharmaceuticals | | 287.0 |
| | 249.3 |
| | 266.8 |
| Total human pharmaceutical products | | 17,269.0 |
| | 20,961.6 |
| | 20,566.9 |
| Animal health | | 2,346.6 |
| | 2,151.5 |
| | 2,036.5 |
| Total segment revenue | | $ | 19,615.6 |
| | $ | 23,113.1 |
| | $ | 22,603.4 |
| | | | | | | | Segment profits(1): | | | | | | | Human pharmaceutical products | | $ | 3,132.0 |
| | $ | 5,015.0 |
| | $ | 4,393.4 |
| Animal health | | 564.2 |
| | 556.6 |
| | 508.1 |
| Total segment profits | | $ | 3,696.2 |
| | $ | 5,571.6 |
| | $ | 4,901.5 |
| | | | | | | | Reconciliation of total segment profits to consolidated income before taxes: | | | | | | | Segment profits | | $ | 3,696.2 |
| | $ | 5,571.6 |
| | $ | 4,901.5 |
| Other profits (losses): | | | | | | | Income related to termination of the exenatide collaboration with Amylin Pharmaceuticals, Inc. (Note 4) | | — |
| | 495.4 |
| | 787.8 |
| Income related to transfer of linagliptin and empagliflozin rights in certain countries to Boehringer Ingelheim (Note 4) | | 92.0 |
| | — |
| | — |
| Acquired in-process research and development (Notes 3 and 4) | | (200.2 | ) | | (57.1 | ) | | — |
| Asset impairment, restructuring, and other special charges (Note 5) | | (468.7 | ) | | (120.6 | ) | | (281.1 | ) | U.S. Branded Prescription Drug Fee | | (119.0 | ) | | — |
| | — |
| Total consolidated income before taxes | | $ | 3,000.3 |
| | $ | 5,889.3 |
| | $ | 5,408.2 |
|
| | 1 | Human pharmaceutical products segment profit includes total depreciation and amortization expense of $1.27 billion, $1.35 billion, and $1.37 billion for the years ended December 31, 2014, 2013, and 2012, respectively. Animal health segment profit includes total depreciation and amortization expense of $111.5 million, $99.4 million, and $91.1 million for the years ended December 31, 2014, 2013, and 2012, respectively. |
|
| Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] |
| | | | | | | | | | | | | | | | | | | | 2014 | | 2013 | | 2012 | Geographic Information | | | | | | | Revenue—to unaffiliated customers(1): | | | | | | | United States | | $ | 9,134.1 |
| | $ | 12,889.7 |
| | $ | 12,313.1 |
| Europe | | 4,506.7 |
| | 4,338.4 |
| | 4,259.7 |
| Japan | | 2,027.1 |
| | 2,063.8 |
| | 2,246.2 |
| Other foreign countries | | 3,947.7 |
| | 3,821.2 |
| | 3,784.4 |
| Revenue | | $ | 19,615.6 |
| | $ | 23,113.1 |
| | $ | 22,603.4 |
| | | | | | | | Long-lived assets(2): | | | | | | | United States | | $ | 4,566.2 |
| | $ | 4,649.6 |
| | $ | 5,064.7 |
| Europe | | 2,401.5 |
| | 2,469.7 |
| | 2,281.1 |
| Japan | | 80.4 |
| | 81.1 |
| | 101.5 |
| Other foreign countries | | 1,499.1 |
| | 1,540.9 |
| | 1,543.2 |
| Long-lived assets | | $ | 8,547.2 |
| | $ | 8,741.3 |
| | $ | 8,990.5 |
|
| | 1 | Revenue is attributed to the countries based on the location of the customer. |
| | 2 | Long-lived assets consist of property and equipment and certain sundry assets. |
|